De Vita S - Search Results

1

A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis.

De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, Campanini M, Naclerio C, Tavoni A, Pietrogrande M, Ferri C, Mascia MT, Masolini P, Zabotti A, Maset M, Roccatello D, Zignego AL, Pioltelli P, Gabrielli A, Filippini D, Perrella O, Migliaresi S, Galli M, Bombardieri S, Monti G. De Vita S, et al. Arthritis Rheum. 2012 Mar;64(3):843-53. doi: 10.1002/art.34331. Arthritis Rheum. 2012. PMID: 22147661 Free article. Clinical Trial.

2

Treatment of giant cell arteritis with cyclophosphamide pulses.

de Vita S, Tavoni A, Jeracitano G, Gemignani G, Dolcher MP, Bombardieri S. de Vita S, et al. J Intern Med. 1992 Oct;232(4):373-5. J Intern Med. 1992. PMID: 1402645 No abstract available.

3

[The diet therapy of rheumatic diseases].

De Vita S, Bombardieri S. De Vita S, et al. Recenti Prog Med. 1992 Dec;83(12):707-18. Recenti Prog Med. 1992. PMID: 1494711 Review. Italian.

4

[Use of high-dose intravenous immunoglobulins in the therapy of connectivitis: preliminary experience in 5 cases].

De Vita S, D'Ascanio A, Bombardieri S. De Vita S, et al. Recenti Prog Med. 1991 Nov;82(11):603-6. Recenti Prog Med. 1991. PMID: 1763234 Italian.

5

Cyclophosphamide pulses in the treatment of rheumatic diseases: an update.

De Vita S, Neri R, Bombardieri S. De Vita S, et al. Clin Exp Rheumatol. 1991 Mar-Apr;9(2):179-93. Clin Exp Rheumatol. 1991. PMID: 2060164 Review. No abstract available.

6

Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community.

Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, Bjerrum KB, Braga S, Coll J, de Vita S, et al. Vitali C, et al. Among authors: de vita s. Arthritis Rheum. 1993 Mar;36(3):340-7. doi: 10.1002/art.1780360309. Arthritis Rheum. 1993. PMID: 8452579

7

High dose intravenous immunoglobulin therapy for rheumatic diseases: clinical relevance and personal experience.

De Vita S, Ferraccioli GF, Di Poi E, Bartoli E, Bombardieri S. De Vita S, et al. Clin Exp Rheumatol. 1996 May-Jun;14 Suppl 15:S85-92. Clin Exp Rheumatol. 1996. PMID: 8828953 Review.

8

Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma.

De Vita S, De Re V, Gasparotto D, Ballarè M, Pivetta B, Ferraccioli G, Pileri S, Boiocchi M, Monteverde A. De Vita S, et al. Among authors: de re v. Arthritis Rheum. 2000 Jan;43(1):94-102. doi: 10.1002/1529-0131(200001)43:1<94::AID-ANR12>3.0.CO;2-8. Arthritis Rheum. 2000. PMID: 10643704 Free article.

9

B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.

Zaja F, Iacona I, Masolini P, Russo D, Sperotto A, Prosdocimo S, Patriarca F, de Vita S, Regazzi M, Baccarani M, Fanin R. Zaja F, et al. Among authors: de vita s. Haematologica. 2002 Feb;87(2):189-95. Haematologica. 2002. PMID: 11836170 Clinical Trial.

10

Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells.

De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G. De Vita S, et al. Among authors: de candia a. Arthritis Rheum. 2002 Aug;46(8):2029-33. doi: 10.1002/art.10467. Arthritis Rheum. 2002. PMID: 12209504 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

450 results

Search Page